Positions

Overview

  • I performed my undergraduate studies in biochemistry and molecular biology at Pennsylvania State University (B.Sc, 2002). For graduate studies I trained with John Kearney, Ph.D. at the University of Alabama at Birmingham (Birmingham, AL). My thesis research focused on understanding the development of serologic and B cell memory to the T cell independent, type 2 antigen alpha 1->3-dextran. After obtaining my Ph.D. in microbiology and immunology, I took a 4 year hiatus from research to obtain my doctorate in veterinary medicine at Auburn University, College of Veterinary Medicine. While at Auburn I obtained additional training in cancer genetics and immunology under the guidance of Dr. Curtis Bird, Ph.D. My research in Dr. Bird’s lab focused on generating a mouse model of the canine immune system, permissible to engraftment of canine peripheral blood mononuclear cells derived from canine patients with mammary cancer. The goal of this work was to model patient immunity to an experimental autologous dendritic cell (derived from patients) – allogeneic canine mammary tumor vaccine. After obtaining my DVM, I went to Johns Hopkins to pursue a residency in veterinary anatomic pathology and postdoctoral research in cancer immunology and translational medicine. While at Johns Hopkins in the departments of Molecular and Comparative Pathobiology and Oncology, I completed my residency training in veterinary anatomic pathology and obtained additional training in tumor immunology and translational medicine with Dr. Leisha Emens (M.D., Ph.D.) My postdoctoral research in Dr. Emens lab focused on evaluating the therapeutic potential of the STING agonist ADU-S100 in combination with immune checkpoint blockade. After completion of my postdoctoral fellowship, I was appointed as a faculty member in the departments of Microbiology and Animal Resources Program where I currently serve as both an investigator in Microbiology and veterinary anatomic pathologist for ARP.
  • Jeremy Foote PhD, DVM, DACVP | Assistant Professor Microbiology
    Director of Comparative Pathology Lab, Animal Resources Program
    Director of the Gnotobiotic and Genetically-Engineered Mouse Core
    UAB | The University of Alabama at Birmingham
    BLDG Abbreviation Suite RSB 250G | 1800 9th Ave. South | Birmingham, AL 35294
    P: 205.975.0688 | jbf130@uab.edu
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2018 STING signaling: A key to therapeutic tumor immunityImmunotherapy.  10:729-731. 2018
    2017 A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized MiceCancer Immunology Research.  5:468-479. 2017
    2017 Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivoInternational Immunopharmacology.  46:112-123. 2017
    2015 A Murine Viral Outgrowth Assay to Detect Residual HIV Type 1 in Patients With Undetectable Viral Loads.Journal of Infectious Diseases.  212:1387-1396. 2015
    2015 Immune targeting in breast cancerOncology.  29. 2015
    2015 Immune targeting in breast cancerOncology.  29:375-385. 2015
    2014 Engraftment of canine peripheral blood lymphocytes into nonobese diabetic-severe combined immune deficient IL-2R common gamma chain null mice.Veterinary Immunology and Immunopathology.  157:131-141. 2014
    2012 A rapid and quantitative method for the evaluation of V gene usage, specificities and the clonal size of B cell repertoiresJournal of Immunological Methods.  376:143-149. 2012
    2012 Long-term maintenance of polysaccharide-specific antibodies by IgM-secreting cellsJournal of Immunology.  188:57-67. 2012
    2011 Membranous glomerulopathy in an adult patient with X-linked agammaglobulinemia receiving intravenous gammaglobulinJournal of Investigational Allergology and Clinical Immunology.  21:405-409. 2011
    2011 Marginal zone B cells regulate antigen capture by marginal zone macrophagesJournal of Immunology.  186:2172-2181. 2011
    2009 Generation of B cell memory to the bacterial polysaccharide α-1,3 dextranJournal of Immunology.  183:6359-6368. 2009
    2006 Fc receptor homolog 3 is a novel immunoregulatory marker of marginal zone and B1 B cellsJournal of Immunology.  177:6815-6823. 2006
    2005 Marginal zone B cells in lymphocyte activation and regulationCurrent Opinion in Immunology.  17:244-250. 2005

    Chapter

    Year Title Altmetric
    2020 Cytokine profiling of tumor-infiltrating T lymphocytes by flow cytometry.  1-20. 2020

    Research Overview

  • Evaluating the Roles of B cells and Antibody in Pancreatic Cancer Progression - Infiltrating pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the United States and it is one of the most fatal human malignancies, with an overall 5-year survival rate of less than 5%. Both response to standard-of-care and immune checkpoint therapies is poor requiring alternate strategies to induce patient-specific immune responses. In pancreatic cancer pro-tumorigenic macrophage, T regulatory cells, myeloid-derived suppressor cells, and tumor-associated fibroblasts are present within the tumor beginning at early pre-invasive stages of pancreatic cancer development. These cellular subsets inhibit T cell activation and CD8+ T cell recruitment into the tumor. Additional studies have implicated tumor infiltrating B cells as a tumor-promoting subset required for epithelial carcinoma progression enhancing tumor cell survival and contributing to chronic inflammatory cues critical to tumor progression. Our preliminary findings in mouse models of Kras-driven pancreatic cancer indicate that antibodies appear to play an important role in promotion of tumor immunity and limiting metastasis. The major goal of my current research focus is to determine requirements for antibody-driven, pancreatic tumor-specific immunity using mouse models that closely recapitulate disease progression observed in patients. Furthermore we intend to elucidate antibody-dependent and independent mechanisms that promote and inhibit cancer progression using spontaneous, orthotopic, and models that mimic metastatic disease using syngenic pancreatic ductal adenocarcinomna cell lines derived from spontaneously formed neoplasms. Ultimately the findings from these studies will be utilized to test novel and modifications to currently existing treatments to harness the therapeutic capabilities of antibody and limit the immune suppressive effects of B cells in the pancreatic tumor microenvironment with the goal of providing novel therapies capable of successful translation into the clinic. As a comparative pathologist for ARP, I also contribute pathology support to research projects bridging a wide span of research areas, including cancer, autoimmunity, mucosal and transplant immunology. These collaborations involve rodent, porcine, primate models and canine cancer patients. The goal of these collaborations is to provide comparative pathology support to investigators in their respective projects.
  • Role of B cells and tumor antigen-specific antibodies in pancreatic cancer progression.
    Comparative pathology
    Comparative oncology
    Gnotobiotics
  • Principal Investigator On

    Investigator On

    Education And Training

  • Johns Hopkins, School of Medicine Oncology, Postdoctoral Fellowship
  • Doctor of Dental Surgery, Auburn University 2013
  • Doctor of Philosophy in Microbiology, University of Alabama at Birmingham 2009
  • Bachelor of Science or Mathematics in Biochemistry and Molecular Biology, The Pennsylvania State University 2002
  • Full Name

  • Jeremy Foote